Cure My Disease

Don't miss your cure!

 Log in / Sign up

Japanese MDS patients under the microscope: what really happens in clinics?

NCT ID NCT06298643

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how 177 people with lower-risk myelodysplastic syndromes (MDS) are treated in real-world clinics across Japan. Researchers collected data on treatments, blood transfusions, and healthcare costs to understand current practice patterns. The goal was to describe outcomes and resource use, not to test a new drug or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

177 people

The number who actually took part.

Started

Dec 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants with myelodysplastic syndrome in Japan

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants with at least one definitive myelodysplastic syndrome (MDS) diagnosis as per the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (MDS; ICD10: D46.X) between 01-May-2017 and 31-Jan-2022 * Participants with confirmed low-risk MDS by International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) during baseline as follows: * Record of low (0 points) or intermediate-1 (\>0 to 1 point) MDS according to IPSS scoring; or * Record of very low (≤1.5), low (\>1.5-3), or intermediate (\>3-4.5) MDS according to IPSS-R scoring; or * Mention of very low, low, intermediate, intermediate-1, or lower risk MDS in the Electronic Medical Records (EMR) * Participants with a record of a confirmed bone marrow procedure (bone marrow aspiration code D404-00 and/or bone marrow biopsy code D404-02) during baseline period Exclusion Criteria: * Participants not meeting the inclusion criteria * Participants \<18 years of age at index date * Participants who have a look back period \<30 days from initial myelodysplastic syndrome diagnosis date

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lower-risk myelodysplastic syndromes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lower-risk myelodysplastic syndromes

Contacts and locations

Locations

  • Mebix, Inc

    Tokyo, Minato-ku, 107-0052, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.